A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer

Journal of Thoracic Oncology

Volumn 10, Issue 1, 2015, Pages 206-211

  Lu, Shun ^a   Li, Lu ^b   Luo, Yi ^c   Zhang, Li ^d   Wu, Gang ^e   Chen, Zhiwei ^a   Huang, Cheng ^f   Guo, Shuliang ^g   Zhang, Yiping ^h   Song, Xiangqun ⁱ   Yu, Yongfeng ^a   Zhou, Caicun ^j   Li, Wei ^k   Liao, Meilin ^a   Li, Baolan ^l   Xu, Liyan ^l   Chen, Ping ^m   Hu, Chunhong ^m   Hu, Chengping ⁿ  

^a SHANGHAI CHEST HOSPITAL   (China)

^b SICHUAN UNIVERSITY   (China)

^c HUNAN CANCER HOSPITAL   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^f FUJIAN PROVINCIAL TUMOR HOSPITAL   (China)

^g CHONGQING MEDICAL UNIVERSITY   (China)

^h ZHEJIANG CANCER HOSPITAL   (China)

ⁱ GUANGXI MEDICAL UNIVERSITY   (China)

^j TONGJI UNIVERSITY   (China)

^k JILIN UNIVERSITY   (China)

^l CAPITAL MEDICAL UNIVERSITY   (China)

^m CENTRAL SOUTH UNIVERSITY   (China)

ⁿ CENTRAL SOUTH UNIVERSITY   (China)

more..

Author keywords

Carboplatin; Etoposide; Extensive stage small cell lung cancer; Rh endostatin; Survival

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; ETOPOSIDE; RECOMBINANT ENDOSTATIN; ANTINEOPLASTIC AGENT; ENDOSTATIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHINESE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ELEVATED BLOOD PRESSURE; FEMALE; FOLLOW UP; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMALL CELL LUNG CANCER; SUPRAVENTRICULAR PREMATURE BEAT; TACHYCARDIA; TREATMENT RESPONSE; WEAKNESS; ADOLESCENT; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MIDDLE AGED; SMALL CELL LUNG CARCINOMA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDOSTATINS; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SMALL CELL LUNG CARCINOMA; YOUNG ADULT;

EID: 84926341135     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000343     Document Type: Article

References (14)

1. Noda K, Nishiwaki Y, Kawahara M, et al Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
2. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:1563-1574.
3. Wang J, Sun Y, Liu Y, et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 2005;8:283-290.
4. Rong B, Yang S, Li W, et al. Systematic review and meta-analysis of Rh-endostatin (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol 2012;10:170.
5. Zhou ZT, Zhou FX, Wei Q, et al. Phase II study of cisplatin/etoposide and rh-endostatin for extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol 2011;68:1027-1032.
6. Horn L, Dahlberg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009;27:6006-6011.
7. Spigel DR, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011;29:2215-2222.
8. Niell HB, Herndon JE 2nd, Miller AA, et al Cancer and Leukemia Group. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005;23:3752-3759.
9. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-2535.
10. Svensson G, Ewers SB, Ohlsson O, Olsson H. Prognostic factors in lung cancer in a defined geographical area over two decades with a special emphasis on gender. Clin Respir J 2013;7:91-100.
11. Kuo YH, Lin ZZ, Yang YY, et al. Survival of patients with small cell lung carcinoma in Taiwan. Oncology 2012;82:19-24.
12. Chen JH, Luo YZ, Zhou WW, et al. Recombinant human endostatin combined carboplatin plus etoposide for advanced small-cell lung cancer. 2014 ASCO Annual Meeting. 2014:e18554.
13. Han B, Xiu Q, Wang H, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with rh-endostatin for advanced non-small cell lung cancer. J Thorac Oncol 2011;6:1104-1109.
14. Ready N, Pang H, Gu L, et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small cell lung cancer: a randomized, placebo controlled phase II study CALGB 30504 (ALLIANCE). 2013 ASCO Annual Meeting. 2013:7506.